Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ISOTRETINOIN

All products: general benefit

Epuris · DIN 02397005 · 30mg · capsule

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Epuris · DIN 02397005 Manufacturer: Cipher Pharmaceuticals Inc.; listing date 2014-02-27 Health Canada: Marketed since 2013-05-07 · brand EPURIS · ATC D10BA01 ISOTRETINOIN · form Capsule · route Oral · ingredients ISOTRETINOIN 30 MG · company Cipher pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Epuris: Formulary list price $2.6871/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6871 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88200 · Verify on the e-Formulary ↗ (DIN 02397005)

Source record
DIN 02397005: Epuris Raw flags: sec3=Y Item: 843600097; group id 864; item number 2089; lccId None; manufacturer id CIP Source form: Cap; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $2.6871; ministry $2.6871 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02397005 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88200 Therapeutic Notes (formulary) Isotretinoin is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne that are unresponsive to conventional therapy including systemic antibiotics. Females of childbearing potential should have a negative pregnancy test within 2 weeks prior to starting treatment. Isotretinoin should be started the second or third day of the next normal menstrual period. Effective contraception should be used for at least 1 month prior to starting isotretinoin, during treatment and for at least 1 month following discontinuation of treatment.
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

FLUOROURACIL

· 1 products · General benefit · strengths: 5% · Cr

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

ALITRETINOIN

· 4 products · Listed, not a benefit (2), Limited Use, codes 442 (2) · strengths: 10mg, 30mg · Cap

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr

RISANKIZUMAB

· 3 products · Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ACCUTANE™ (isotretinoin) is indicated for the treatment of: • Severe Nodular and/or Inflammatory Acne • Acne Conglobata • Recalcitrant Acne Because of significant side effects associated with its use, ACCUTANE should be reserved for patients where the conditions listed above are unresponsive to conventional first line therapies. ACCUTANE should only be prescribed by physicians knowledgeable in the use of retinoids systemically, who understand the risk of teratogenicity in females of child bearing age and who are experienced in counselling young adults for whom ACCUTANE is generally indicated (see 2 CONTRAINDICATIONS, 3 SERIOUS WARNINGS AND PRECAUTIONS BOX and 7.1.1 Pregnant Women). A careful assessment of the patient’s mental state should be made, including whether or not they have a history of previous psychiatric illness (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Psychiatric). It is strongly recommended that each ACCUTANE prescription be limited to a one-month supply in order to encourage patients to return for follow-up to monitor side-effects. The pharmacist must ensure that: • Prescriptions of ACCUTANE for women of child-bearing potential sho… https://pdf.hres.ca/dpd_pm/00081681.PDF PM date: SEP 05, 2025 Source product: ACCUTANE; DIN 00582344; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.